Table 3.
Preliminary study results of different doses of zerumbone.
| Group | n | AMY (U/L) | sPLA2 (U/L) | ALT (U/L) |
|---|---|---|---|---|
| Sham-operated group | 8 | 1304.8 ± 114.7 | 519.7 ± 63.9 | 95.7 ± 7.9 |
| Acute necrotizing pancreatitis group | 8 | 6774.8 ± 739.0a | 789.0 ± 124.2a | 257.6 ± 41.7a |
| Zerumbone pretreated group 5 mg/kg | 8 | 5279.5 ± 857.4a,b | 775.5 ± 160.9a | 230.1 ± 50.4a |
| Zerumbone pretreated group 10 mg/kg | 8 | 3342.6 ± 542.4a,b,c | 621.7 ± 73.8 | 157.5 ± 31.2a,b |
| Zerumbone pretreated group 20 mg/kg | 8 | 3440.9 ± 575.9a,b,c | 625.9 ± 108.9 | 181.7 ± 30.3a,b |
| Zerumbone pretreated group 40 mg/kg | 8 | 3073.7 ± 461.5a,b,c | 667.0 ± 108.2a | 245.8 ± 30.5a |
Rats from different groups were ended at 12 h after sodium taurocholate infusion. The serum amylase (AMY), secretory phospholipase A2 (sPLA2), and alanine aminotransferase (ALT) in serum was measured by an automatic biochemistry analyzer with standard techniques (Olympus Optical Ltd., Japan). Data were expressed as means ± standard error values. a P < 0.05 versus sham-operated group. b P < 0.05 versus acute necrotizing pancreatitis group. c P < 0.05 versus zerumbone pretreated group 5 mg/kg.